Israel - English - Ministry of Health

propharm ltd - baclofen - solution for injection - baclofen 10 mg / 5 ml - baclofen - baclofene bioindustria l.i.m. 10mg/5ml is indicated in patients with severe chronic spasticity resulting from trauma, multiple sclerosis or other spinal cord disorders, who are unresponsive to oral baclofen or other orally administered antispastic agents and/or those patients who experience unacceptable side effects at effective oral doses.baclofene bioindustria l.i.m. 10mg/5ml is effective in adult patients with severe chronic spasticity of cerebral origin, resulting e.g. from cerebral palsy, brain trauma or cerebrovascular accident; however, clinical experience is limited.pediatric population:baclofene bioindustria l.i.m. 10mg/5ml is indicated in patients aged 4 to <18 years with severe chronic spasticity of cerebral origin or of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - baclofen 2 mg/ml - solution for injection - 10 mg/5ml - active: baclofen 2 mg/ml excipient: sodium chloride water for injection - indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - baclofen 0.5 mg/ml - solution for injection - 10 mg/20ml - active: baclofen 0.5 mg/ml excipient: sodium chloride water for injection - indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - baclofen, quantity: 10 mg - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; sodium starch glycollate; lactose monohydrate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica - the suppression of voluntary muscle spasm in: multiple sclerosis, spinal lesions of traumatic, infectious, degenerative, neoplastic and unknown origin, causing: skeletal hypertonus, spastic and dyssynergic bladder dysfunction. baclofen is not recommended in parkinson's disease or spasticity arising from strokes, cerebral palsy or rheumatoid disorders.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

strides pharma uk ltd - baclofen - oral tablet - 10mg

New Zealand - English - Medsafe (Medicines Safety Authority)

alpha pharmaceuticals limited - baclofen 10mg - tablet - 10 mg - active: baclofen 10mg excipient: lactose monohydrate magnesium stearate sodium starch glycolate starch

New Zealand - English - Medsafe (Medicines Safety Authority)

medra & pharma services limited - baclofen 10mg - tablet - 10 mg - active: baclofen 10mg excipient: lactose monohydrate magnesium stearate maize starch sodium starch glycolate

Canada - English - Health Canada

pharmascience inc - baclofen - tablet - 20mg - baclofen 20mg - gaba-derivative skeletal muscle relaxants

Canada - English - Health Canada

dominion pharmacal - baclofen - tablet - 20mg - baclofen 20mg - gaba-derivative skeletal muscle relaxants

Canada - English - Health Canada

pharmel inc - baclofen - tablet - 20mg - baclofen 20mg - gaba-derivative skeletal muscle relaxants